Disease modification arrives — and the system starts counting the cost

The integrated read

Disease modification arrives on a surrogate endpoint

The FDA approved teplizumab for children and adolescents with recently diagnosed Stage 3 type 1 diabetes [16]. Stage 3 is diagnosed disease; Stage 2 is the earlier stage, found by screening, where teplizumab has been available to delay onset. Teplizumab acts on the disease process rather than replacing the insulin that process takes away. The clearance came through the accelerated pathway on a surrogate measure. In the PROTECT trial, teplizumab met its primary endpoint on C-peptide, a marker of surviving β-cell function, while the clinical secondary endpoints did not move [7].

A Pediatric Endocrine Society committee post set out who to treat and when: within eight weeks of diagnosis, at least one positive islet autoantibody, preserved β-cell function. It reported safety consistent with what had already been seen at Stage 2 [14], and early clinician reaction was enthusiasm tempered by the surrogate endpoint and by not knowing how long the effect lasts [20]. At Stage 2, only about 36% of eligible patients started the drug; cost, logistics and treatment burden were the reasons given, in a report published days before this approval [19]. Whether newly diagnosed families behave the same way is unknown.

The drugs reached surgical-range weight loss, and one hormone fell short on blood sugar

The weight-loss numbers kept climbing, though not all of them landed in June. Orforglipron, an oral non-peptide GLP-1, took 9.6% of body weight off at 72 weeks on its 36 mg dose in the ATTAIN-2 trial, against 2.5% on placebo, published in November 2025 and still setting the terms [5]. A pill changes how many people a drug can reach. At the ADA Scientific Sessions in June, retatrutide, which drives the GLP-1, GIP and glucagon receptors together, put 45.3% of patients on its 12 mg dose past 30% body-weight loss in the TRIUMPH-1 trial, with a 28.3% mean reduction across 2,339 adults who had obesity or overweight without diabetes [6]. Losses of that size were once reserved for surgery. Lilly reported that figure itself, and the trade article covering it is paywalled, so we read only the headline and the visible summary.

One result went the opposite way. GIP is one of the three receptors retatrutide drives; this study infused the natural hormone itself. In 61 adults with type 2 diabetes, GIP given for six weeks, alone or added to semaglutide, did not reach the prespecified glycaemic target [8]. With 16% of participants discontinuing, the authors say they cannot draw firm conclusions about GIP added to placebo. A negative result deserved more attention than it got, in a field busy adding one drug to another.

The rules changed as fast as the drugs did

In the ADA’s 2026 Standards of Care [13], section 7 gives automated insulin delivery a grade A recommendation in type 1 diabetes and, for the first time, in adults with type 2; continuous glucose monitoring is recommended more widely; and GLP-1s appear in the type 1 guidance. The Standards were announced in December 2025 and published in the January 2026 supplement, so they set the rules that applied during June rather than being a June event.

The FDA moved in both directions across the quarter. In June it cleared the first over-the-counter continuous glucose monitor for children [17]. The clearance covers ages two and up who do not use insulin, which excludes the type 1 patients this issue is largely about, and it is not indicated where low blood sugar is a problem. Six weeks earlier, at the end of April, it had proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulk-substances list [18], beginning to close the compounded-GLP-1 era by restricting supply.

The bill arrives before the benefit is established

In late May, the pharmacy benefit manager CVS Caremark put Lilly on the same terms as Novo Nordisk, adding Lilly’s Foundayo pill and returning Zepbound to the list of drugs it covers from 1 October; Novo’s Wegovy pill and injection stay preferred as well [9]. Nobody lost preferred status. Novo lost exclusivity, and with efficacy settled, the list a benefit manager covers now moves more prescriptions than a new trial result does.

US health spending reached $5.7 trillion in 2025, up 7.3% on the year and on pace to pass $6 trillion in 2026, with GLP-1s named as a driver [10]. McKinsey sizes the market at roughly 900 million adults with obesity, prescriptions growing 38% a year, and sales heading toward $100B by 2030 [11]. They frame the choice as treating obesity reactively or getting ahead of it through prevention [12]. Those are cited positions, not ours. The population in question is larger than a US argument suggests: the IDF Diabetes Atlas puts 11.1% of adults aged 20 to 79, about one in nine, as living with diabetes, and projects about 853 million by 2050 [15].

The science stopped being about glucose

Away from the clinic, a genetic analysis of circulating metabolic traits in 619,372 individuals [1] gives the data needed to work out who is at risk and why, far upstream of blood sugar. A separate paper traced how glycogen drives the sensory activation of POMC neurons [2], the appetite circuitry the incretin drugs ultimately act on. A preclinical study tied a methionine-supplemented diet to raised GLP-1 and FGF21 and to healthspan [3], work that treats metabolism as part of the biology of ageing.

A preprint linked what happens to β-cells under nutrient stress in the dish to population genetics [4]. It is not peer-reviewed, and in that design the claim is only as good as the methods.

What this means for you

The trials behind this issue

The trials this issue draws on, with what each has and has not shown.

Sources

Every source behind the read above, numbered to its [n] marker and graded by where its evidence comes from.

Source gradeRegulatoryGuidelineTrialPeer-reviewedPreprintConsultingTrade press

Literature

1. Peer-reviewed Genetic analysis of circulating metabolic traits in 619,372 individuals Nature
2. Peer-reviewed Glycogen drives the sensory activation of POMC neurons Nature Metabolism
3. Peer-reviewed Methionine-supplemented longevity diet increases growth hormone, GLP-1, and FGF21; reduces frailty; and promotes healthspan Cell Metabolism · preclinical
4. Preprint Dish-to-biobank: β-cell nutrient-stress programs linked to T2D genetic and dietary risk bioRxiv · posted 16 June 2026 · not peer-reviewed · in this design the claim is only as good as the methods

Trials & clinical

5. Trial ATTAIN-2: orforglipron, an oral small-molecule GLP-1, in type 2 diabetes & obesity The Lancet · published online 20 November 2025 · phase 3 · orforglipron 36 mg, −9.6% vs −2.5% placebo at week 72 · interest: funded by Eli Lilly, which makes orforglipron
6. Trade press TRIUMPH-1: retatrutide, 45.3% of patients on the 12 mg dose lost ≥30% of body weight reported at ADA Scientific Sessions, 6 June 2026 · 2,339 adults with obesity or overweight without diabetes, 80 weeks, −28.3% mean · figure reported by Lilly itself; trade coverage is paywalled, so we saw only the headline and summary · interest: Eli Lilly, which makes retatrutide
7. Trial PROTECT: teplizumab preserves β-cell function in newly diagnosed children NEJM, 2023 · basis for the 2026 accelerated approval · interest: funded by Provention Bio and Sanofi
8. Trial Native GIP, alone or added to semaglutide, did not improve glycemia Lancet Diabetes & Endocrinology · 22 May 2026 · n=61 adults with type 2 diabetes, 6-week infusion · interest: funded by Novo Nordisk, which makes the GLP-1-only semaglutide and competes with GLP-1/GIP dual agonists

Industry & deals

9. Trade press CVS Caremark drops Novo's preferred edge — adds Lilly's Foundayo pill and Zepbound BioPharma Dive · 28 May 2026 · Novo's Wegovy pill and injection remain preferred; Zepbound returns 1 October
10. Trade press U.S. health spending hit $5.7 trillion in 2025 and is on pace to top $6 trillion in 2026, with GLP-1s a named driver STAT · 24 June 2026 · paywalled, headline and visible summary only · underlying data: Health Affairs/CMS

Consulting & strategy

11. Consulting GLP-1s are changing obesity care. What comes next? — McKinsey McKinsey
12. Consulting The metabolic health revolution has arrived — McKinsey Health Institute McKinsey Health Institute

Policy & guidelines

13. Guideline ADA Standards of Care 2026: automated insulin delivery becomes preferred; GLP-1s enter type 1 guidance American Diabetes Association · announced 8 December 2025; Standards published in Diabetes Care 2026;49(Suppl 1), §7 — the section, not the release, carries these recommendations
14. Guideline Pediatric Endocrine Society: initiation criteria for teplizumab in practice Pediatric Endocrine Society · 23 June 2026 · Drug & Therapeutics Committee post, not formal guidance
15. Guideline IDF Diabetes Atlas: 11.1% of adults aged 20–79 live with diabetes; ~853M projected by 2050 International Diabetes Federation · adults aged 20–79 · 852.5M projected for 2050, about 1 in 8
16. Regulatory FDA approves teplizumab for recently-diagnosed Stage 3 pediatric T1D FDA
17. Regulatory FDA clears first OTC continuous glucose monitor for children aged 2+ who do not use insulin FDA
18. Regulatory FDA proposes excluding semaglutide, tirzepatide, liraglutide from 503B bulks list FDA · 30 April 2026

Commentary

19. Trade press Only ~36% of eligible patients started teplizumab — cost, logistics, and treatment burden cited diaTribe
20. Trade press Teplizumab approved for pediatric Stage 3 T1D — what clinicians are saying Medscape

About this brief

Radar scans six source-worlds each month: the literature, registered trials, industry and deals, the consulting firms, policy and regulators, and field commentary. It then surfaces the items that matter and grades each by where its evidence comes from. Consulting analyses are cited, never presented as ours. This is issue No. 1; the source list grows as the scanner's coverage widens.